RFA-NS-21-022: Translational Neural Devices (U44 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $1.0 million to small businesses. It expected to make $4.0 million in total. Applications closed on December 20, 2022.
From the official notice on Grants.gov, last changed January 6, 2023. Checked November 7, 2026.
- Award ceiling$1.0 million
- Total funding$4.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU44
- Clinical trialsOptional
- Funded byNINDS
- Median yearly award$1.3 million
- Typical project length4.5 years
Projects funded under RFA-NS-21-022 were run by National Institute of Neurological Disorders and Stroke (NINDS, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-21-022 in the NIH Guide.
Key dates
| Posted | April 28, 2021 |
|---|---|
| Deadline | December 20, 2022 |
| Archived by Grants.gov | January 19, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.3 million; it allows up to $1.0 million per award.
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.
Funded under RFA-NS-21-022 so far
NIH funded 3 projects under RFA-NS-21-022 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $1.3 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Facilitating neuroplastic changes of acute stroke survivors with severe hemiplegia | Rehabtek, LLC | 2026 | $1.3 million |
| The Neurospan Bridge: A Device for Peripheral Nerve Repair | Auxilium Biotechnologies Inc. | 2026 | $1.5 million |
| Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac Arrest | Mitovation, Inc. | 2026 | $1.5 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-21-022 still open?
No. It closed on December 20, 2022.
Who can apply for Translational Neural Devices (U44 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Translational Neural Devices (U44 Clinical Trial Optional)?
Closed December 20, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each. About $4.0 million in total.
Who has been funded under RFA-NS-21-022?
NIH RePORTER lists 3 projects funded under RFA-NS-21-022 in fiscal 2022 to 2026, at 3 institutions. The most were at Rehabtek, LLC, Auxilium Biotechnologies Inc., Mitovation, Inc.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)